Key result
Amiodarone reduced the risk of sudden cardiac death compared to placebo or control (7.1% vs. 9.7%; OR 0.71; 95% CI 0.61-0.84; P<0.001), though it increased pulmonary and thyroid toxicity.
Why the study?
Does amiodarone reduce sudden cardiac death in patients at risk for SCD?
Population
8,522 patients at risk for sudden cardiac death (SCD) pooled from 15 randomized controlled trials
Comparison
Amiodarone vs Placebo or control
Design
Meta-analysis
Authors
Loading...
Amiodarone reduces SCD incidence; supports use where ICD access is limited and strengthens evidence for guideline consideration.
Meta-Analysis (n=8,522)
Does amiodarone reduce sudden cardiac death in patients at risk for SCD?
Odds Ratio: 0.71 (95% CI 0.61–0.84)
Absolute Event Rate: 7.1% vs 9.7%
p-value: p=< 0.001
Amiodarone reduces the risk of sudden cardiac death by 29% and cardiovascular death by 18%, offering a viable alternative for patients ineligible for ICDs, though it significantly increases pulmonary and thyroid toxicity.
Piccini et al. (2009) conducted a meta-analysis in at risk for sudden cardiac death (SCD) (n=8,522). Amiodarone vs. placebo/control was evaluated on sudden cardiac death (SCD) (OR 0.71, 95% CI 0.61-0.84, p=< 0.001). Amiodarone reduced the risk of sudden cardiac death compared to placebo or control (7.1% vs. 9.7%; OR 0.71; 95% CI 0.61-0.84; P<0.001), though it increased pulmonary and thyroid toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: